On the public citation graph
Process Choice Under Asymmetric Competition with Exogenous and Endogenous Product Success Probabilities
0 signed · 35 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1007/s00712-014-0415-3openalex-extracted
Competition, innovation, and the effect of R&D knowledge
inferredcites →https://doi.org/10.1016/j.ejor.2008.05.030openalex-extracted
Optimal overlapping and functional interaction in product development
inferredcites →https://doi.org/10.1016/j.ejor.2009.03.040openalex-extracted
Overlapping and communication policies in product development
inferredcites →https://doi.org/10.1016/j.ejor.2013.04.002openalex-extracted
New product introduction and capacity investment by incumbents: Effects of size on strategy
inferredcites →https://doi.org/10.1016/j.ejor.2018.08.049openalex-extracted
Entry deterrence by timing rather than overinvestment in a strategic real options framework
inferredcites →https://doi.org/10.1016/j.ejor.2019.02.012openalex-extracted
Dynamic pricing and competitive time-to-market strategy of new product launch under a multistage duopoly
inferredcites →https://doi.org/10.1016/j.ejor.2022.06.046openalex-extracted
Dynamic investment strategies and leadership in product innovation
inferredcites →https://doi.org/10.1038/d41586-021-03410-9openalex-extracted
More Alzheimer’s drugs head for FDA review: what scientists are watching
inferredcites →https://doi.org/10.1080/24725854.2020.1830207openalex-extracted
Faster or fewer iterations? A strategic perspective of a sequential product development project
inferredcites →https://doi.org/10.1109/tem.2017.2654223openalex-extracted
A Method for Improving Overlapping of Testing and Design
inferredcites →https://doi.org/10.1109/tem.2019.2929660openalex-extracted
Managing the Development of Complex Product Systems: An Integrative Literature Review
inferredcites →https://doi.org/10.1111/deci.12283openalex-extracted
Supplier Innovation Strategy and Performance: A Matter of Supply Chain Market Positioning
inferredcites →https://doi.org/10.1111/j.1937-5956.2010.01165.xopenalex-extracted
Managing Technology Selection and Development Risk in Competitive Environments
inferredcites →https://doi.org/10.1111/poms.13266openalex-extracted
Performance, Reliability, or Time‐to‐Market? Innovative Product Development and the Impact of Government Regulation
inferredcites →https://doi.org/10.1111/poms.14048openalex-extracted
Sequential versus concurrent final phase product development: Approval uncertainty, time‐sensitive consumers, asymmetric competition, and government subsidy
inferredcites →https://doi.org/10.1287/mnsc.1090.1061openalex-extracted
Swift and Smart: The Moderating Effects of Technological Capabilities on the Market Pioneering–Firm Survival Relationship
inferredcites →https://doi.org/10.1287/mnsc.1110.1309openalex-extracted
Capacity Investment Timing by Start-ups and Established Firms in New Markets
inferredcites →https://doi.org/10.1287/mnsc.2022.4303openalex-extracted
I Don’t “Recall”: The Decision to Delay Innovation Launch to Avoid Costly Product Failure
inferredcites →https://doi.org/10.1287/mnsc.42.2.173openalex-extracted
New Product Development: The Performance and Time-to-Market Tradeoff
inferredcites →https://doi.org/10.1287/mnsc.43.4.437openalex-extracted
A Model-Based Framework to Overlap Product Development Activities
inferredcites →https://doi.org/10.1287/mnsc.47.1.1.10668openalex-extracted
Product Development Decisions: A Review of the Literature
inferredcites →https://doi.org/10.1287/msom.2.1.1.23266openalex-extracted
Sustaining Technology Leadership Can Require Both Cost Competence and Innovative Competence
inferredcites →https://doi.org/10.1287/msom.2016.0610openalex-extracted
Note on Cournot Competition Under Yield Uncertainty
inferredcites →https://doi.org/10.1287/msom.2020.0895openalex-extracted
Sequential Product Development and Introduction by Cash-Constrained Start-Ups
inferredcites →https://doi.org/10.1287/opre.1040.0157openalex-extracted
Optimal Product Launch Times in a Duopoly: Balancing Life-Cycle Revenues with Product Cost
inferredcites →https://doi.org/10.1509/jmkg.67.3.1.18652openalex-extracted
What Will the Future Bring? Dominance, Technology Expectations, and Radical Innovation
inferredcites →https://doi.org/10.2139/ssrn.2677096openalex-extracted
Entry Deterrence by Timing Rather than Overinvestment in a Strategic Real Options Framework
inferredcites →https://doi.org/10.2139/ssrn.2930845openalex-extracted
Dynamic Investment Strategies and Leadership in Product Innovation
inferredcites →https://doi.org/10.2139/ssrn.2955332openalex-extracted
Performance, Reliability or Time-To-Market? Innovative Product Development and the Impact of Government Regulation
inferredcites →https://doi.org/10.2307/3087441openalex-extracted
An R&D Race with Knowledge Accumulation
inferredcites →https://doi.org/10.1287/msom.1080.0242openalex-snapshot
Cournot Competition Under Yield Uncertainty: The Case of the U.S. Influenza Vaccine Market
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.